Navigation Links
AtheroNova Announces Milestone Filing of IND in Russian Federation
Date:11/13/2012

IRVINE, Calif., Nov. 13, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that its Russian licensing partner OOO CardioNova has formally submitted its Investigational New Drug (IND) application with the Ministry of Health of the Russian Federation (Minzdrav).  This filing is the first step in the process of obtaining approval in Russia to conduct the Phase 1 human clinical trials in the centers selected by CardioNova.  It is expected that the approval of the application will be granted by the Ministry early in 2013 and the Phase 1 will commence shortly thereafter.

"We are extremely gratified in achieving this milestone in our path to human trials of AHRO-001," said AtheroNova CEO Thomas W. Gardner.  "OOO CardioNova has diligently pushed this filing forward with the utmost urgency and we want to thank them for their efforts to complete this major step in the process of clinical development of AHRO-001.  We continue to work aggressively toward our mutual goal of commencement of Phase 1 clinical trials within the next 90 days."

"We are pleased to have such a tremendous business partner in AtheroNova as we continue to endeavor toward approval of the Phase 1 protocol by the Ministry of Health," commented Dr. Alexey Eliseev, managing partner of Maxwell Biotech Group, OOO CardioNova's parent company. "Our objective is to work diligently with the Ministry of Healthcare for approval of our submission while making final preparations for the commencement of pre-screening and ultimately Phase 1 clinical trials in our Russian study centers.  We are excited with the prospect of initiating clinical trials in anticipation of potentially addressing one of the major health risks facing Russia, and throughout the world.

About AHRO-001

AHRO-001 is AtheroNova's first novel application for the treatment and prevention of atherosclerosis. Atherosclerotic plaque is the primary, underlying cause of heart disease and stroke in industrialized countries. AHRO-001 uses certain pharmacological compounds to regress atherosclerotic plaque deposits through a process known as delipidization. Delipidization dissolves plaques in artery walls, which are then removed by natural body processes. AtheroNova is developing, and seeks to eventually market AHRO-001, a product that has the potential to become a new standard of care for patients prone to atherosclerotic plaque accumulation.

About AtheroNova

AtheroNova Inc., through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits and to safely improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please visit www.AtheroNova.com.

About Maxwell Biotech Group

Maxwell Biotech Group is a development partner and financial resource for biotechnology companies. Maxwell provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Maxwell's unique business model can add value to its partners' pipelines and provide a commercialization path to one of the most lucrative emerging markets. Maxwell relies on an experienced international team of managers and financial and industry experts, with offices in Moscow, Boston and San Diego.

About OOO CardioNova

OOO CardioNova is an operational company in the Russian Federation founded by Maxwell Biotech Group to conduct clinical trials of AHRO-001, seek its approval, and then commercialize it in the territories covered by the license agreement.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the Company's product shipments, suitability of the compound for its intended use, mechanisms of action, clinical trials and supply chain as well as the development of applications for AtheroNova's technology. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
2. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
3. Remedy Informatics Announces Growth Capital Investment from Merck Global Health Innovation Fund
4. RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer
5. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
6. Developmental Disabilities Software announces Safe Harbor Self-Certification Compliance
7. Hologic Announces Fourth Quarter and Fiscal 2012 Operating Results
8. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
9. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
10. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
11. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
Breaking Medicine Technology:
(Date:4/24/2017)... , ... April 24, 2017 , ... Come to PAINWeekEnd ... 4200 Jim Walter Blvd, for an educational and exciting 2-day program. , An ... staff hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing ...
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... , ... “Reflections of God’s Work”: an enlightening collection of life lessons leading ... of published author, Jerri Broglin, a survivor of great loss who gained insight on ... eye-opener for those searching for answers, as we are finding the answers that are ...
(Date:4/24/2017)... , ... April 24, 2017 , ... “The Saint with ... with Trin, and Omega Station” is the creation of published author, Chris Jackson. ... Metroplex where he works in the Dallas Independent School District teaching English. He is ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Life of ... University of Florida. The event will be held at 7:30 pm on May 10th ... Block and Drew Copeland of Sister Hazel, will support the UF Collegiate Recovery Community ...
Breaking Medicine News(10 mins):